[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334616-105":59,"doc-detail-334616-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tyrosine-phosphatase-ptpn11-shp2-in-solid-tumors-bulls-eye-for-targeted-therapy","Tyrosine phosphatase PTPN11/ SHP2 in solid tumors - bull’s eye for targeted therapy?","","Tyrosine phosphatase PTPN11/SHP2 integrates signals from membrane receptors such as RTKs, cytokine and integrin receptors, promoting cell survival and proliferation. While activating PTPN11 mutations mainly drive hematological malignancies, aberrant SHP2 expression or activation influences the development, progression, and metastasis of many solid tumors. SHP2 participates in multiple pathways including RAS-RAF-MEK-ERK, PI3K-AKT, JAK-STAT, and PD-L1/PD-1, showing context-dependent tumor-promoting or tumor-suppressive roles. The article reviews SHP2 molecular functions and the relevance of SHP2 expression across solid tumor entities, including tumor microenvironment and therapy resistance, and discusses current clinical trial opportunities and limitations of allosteric SHP2 inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tyrosine-phosphatase-ptpn11-shp2-in-solid-tumors-bulls-eye-for-targeted-therapy/334616/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tyrosine-phosphatase-ptpn11-shp2-in-solid-tumors-bulls-eye-for-targeted-therapy/334616.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does SHP2 play in cellular signaling in solid tumors?","Question",{"text":112,"@type":113},"SHP2 integrates signals from multiple membrane-bound receptors and operates through several signaling cascades. It functions as a tyrosine phosphatase that can enhance downstream signaling by dephosphorylating regulators.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Are SHP2 alterations in solid tumors driven by PTPN11 mutations?",{"text":117,"@type":113},"Activating PTPN11 mutations are common in leukemia but are rarely found in solid tumors. In solid tumors, SHP2 expression or activation can be aberrant and is linked to tumor development, progression, and metastasis.",{"name":119,"@type":110,"acceptedAnswer":120},"Which major signaling pathways are associated with SHP2 activity?",{"text":121,"@type":113},"The text links SHP2 to RAS-RAF-MEK-ERK, PI3K-AKT, JAK-STAT, NF-kB, and PD-L1/PD-1 pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334616,1790870553,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","TYPE Review  \nPUBLISHED 05 March 2024  \nDOI 10.3389/fimmu.2024.1340726  \nOPEN ACCESS  \nEDITED BY  \nLorenzo Stella,  \nUniversity of Rome Tor Vergata, Italy  \nREVIEWED BY  \nLuis E. Arias-Romero,  \nNational Autonomous University  \nof Mexico, Mexico Claudio Sorio, University of Verona, Italy  \n*CORRESPONDENCE Dietrich Alexander Ruess  \n [dietrich.ruess@uniklinik-freiburg.de](dietrich.ruess@uniklinik-freiburg.de)  \nRECEIVED 18 November 2023  \nACCEPTED 19 February 2024  \nPUBLISHED 05 March 2024  \nCITATION  \nChen X, Keller SJ, Hafner P, Alrawashdeh AY, Avery TY, Norona J, Zhou J and Ruess DA (2024) Tyrosine phosphatase PTPN11/  \nSHP2 in solid tumors-bull ’s eye for targeted therapy?  \nFront. Immunol. 15:1340726 .  \ndoi: 10.3389/fimmu.2024.1340726  \nCOPYRIGHT  \n© 2024 Chen, Keller, Hafner, Alrawashdeh, Avery, Norona, Zhou and Ruess. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTyrosine phosphatase PTPN11/ SHP2 in solid tumors-bull’s eye for targeted therapy?  \nXun Chen 1,2, Steffen Johannes Keller 1, Philipp Hafner 1, Asma Y. Alrawashdeh 1, Thomas Yul Avery1, Johana Norona 1,3, Jinxue Zhou 2 and Dietrich Alexander Ruess 1,3*  \n1 Department of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Freiburg, Germany, 2 Department of Hepatobiliary and Pancreatic Surgery, The Afﬁliated Tumor Hospital of Zhengzhou University, Zhengzhou, China, 3German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany  \nEncoded by PTPN11, the Src-homology 2 domain-containing phosphatase 2 (SHP2) integrates signals from various membrane-bound receptors such as receptor tyrosine kinases (RTKs), cytokine and integrin receptors and thereby promotes cell survival and proliferation. Activating mutations in the PTPN11 gene may trigger signaling pathways leading to the development of hematological malignancies, but are rarely found in solid tumors. Yet, aberrant SHP2 expression or activation has implications in the development, progression and metastasis of many solid tumor entities. SHP2 is involved in multiple signaling cascades, including the RAS-RAF-MEK-ERK-, PI3K-AKT-, JAK-STAT- and PD-L1/PD-1-pathways. Although not mutated, activation or functional requirement of SHP2 appears to play a relevant and context-dependent dichotomous role. This mostly tumor-promoting and infrequently tumor-suppressive role exists in many cancers such as gastrointestinal tumors, pancreatic, liver and lung cancer, gynecological entities, head and neck cancers, prostate cancer, glioblastoma and melanoma. Recent studies have identiﬁed SHP2 as a potential biomarker for the prognosis of some solid tumors. Based on promising preclinical work and the advent of orally available allosteric SHP2-inhibitors early clinical trials are currently investigating SHP2-directed approaches in various solid tumors, either as a single agent or in combination regimes. We here provide a brief overview of the molecular functions of SHP2 and collate current knowledge with regard to the signiﬁcance of SHP2 expression and function in different solid tumor entities, including cells in their microenvironment, immune escape and therapy resistance. In the context of the present landscape of clinical trials withallosteric SHP2-inhibitors we discuss the multitude of opportunities but also limitations of a strategy targeting this non-receptor protein tyrosine phosphatase for treatment of solid tumors.  \nKEYWORDS  \nSHP2, solid tumor, signaling pathway, tumor microenvironment, immune microenvironment, therapy resistance  \nFront","cbCaidD44Ru8D2Hj","https://ap.wps.com/l/cbCaidD44Ru8D2Hj","pdf",2518431,22,"English","# Introduction\n## SHP2 as a signaling hub and biological switch\n# RAS/RAF-MEK-ERK, PI3K-AKT, JAK-STAT and immune-related pathways\n# SHP2 roles across solid tumor entities\n## Tumor microenvironment, immune escape and therapy resistance\n# Clinical landscape of allosteric SHP2 inhibitors","[{\"question\":\"What role does SHP2 play in cellular signaling in solid tumors?\",\"answer\":\"SHP2 integrates signals from multiple membrane-bound receptors and operates through several signaling cascades. It functions as a tyrosine phosphatase that can enhance downstream signaling by dephosphorylating regulators.\"},{\"question\":\"Are SHP2 alterations in solid tumors driven by PTPN11 mutations?\",\"answer\":\"Activating PTPN11 mutations are common in leukemia but are rarely found in solid tumors. In solid tumors, SHP2 expression or activation can be aberrant and is linked to tumor development, progression, and metastasis.\"},{\"question\":\"Which major signaling pathways are associated with SHP2 activity?\",\"answer\":\"The text links SHP2 to RAS-RAF-MEK-ERK, PI3K-AKT, JAK-STAT, NF-kB, and PD-L1/PD-1 pathways.\"}]","Tyrosine phosphatase PTPN11/ SHP2 in solid tumors - bull’s eye for targeted therapy? | PDF",1790007490,55]